JP4948418B2 - Ｎｋｔ細胞を抑制するための方法 - Google Patents

Ｎｋｔ細胞を抑制するための方法 Download PDF

Info

Publication number
JP4948418B2
JP4948418B2 JP2007539372A JP2007539372A JP4948418B2 JP 4948418 B2 JP4948418 B2 JP 4948418B2 JP 2007539372 A JP2007539372 A JP 2007539372A JP 2007539372 A JP2007539372 A JP 2007539372A JP 4948418 B2 JP4948418 B2 JP 4948418B2
Authority
JP
Japan
Prior art keywords
cells
composition
administration
galactosylceramide
nkt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007539372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518974A5 (https=
JP2008518974A (ja
Inventor
サミュエル ストローバー，
エベレット ハートー マイヤー，
デール ティー． ウメツ，
Original Assignee
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ filed Critical ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Publication of JP2008518974A publication Critical patent/JP2008518974A/ja
Publication of JP2008518974A5 publication Critical patent/JP2008518974A5/ja
Application granted granted Critical
Publication of JP4948418B2 publication Critical patent/JP4948418B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2007539372A 2004-11-02 2005-11-02 Ｎｋｔ細胞を抑制するための方法 Expired - Fee Related JP4948418B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US60/624,568 2004-11-02
US70654805P 2005-08-08 2005-08-08
US60/706,548 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (3)

Publication Number Publication Date
JP2008518974A JP2008518974A (ja) 2008-06-05
JP2008518974A5 JP2008518974A5 (https=) 2008-11-27
JP4948418B2 true JP4948418B2 (ja) 2012-06-06

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539372A Expired - Fee Related JP4948418B2 (ja) 2004-11-02 2005-11-02 Ｎｋｔ細胞を抑制するための方法

Country Status (11)

Country Link
US (2) US7682614B2 (https=)
EP (1) EP1812015B1 (https=)
JP (1) JP4948418B2 (https=)
CN (1) CN101031307B (https=)
AT (1) ATE539757T1 (https=)
AU (1) AU2005310247A1 (https=)
CA (1) CA2584971C (https=)
DK (1) DK1812015T3 (https=)
ES (1) ES2378076T3 (https=)
PT (1) PT1812015E (https=)
WO (1) WO2006060117A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372668B1 (en) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
EP2575824A4 (en) * 2010-05-24 2014-02-19 Childrens Medical Center METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
WO2012069572A1 (en) * 2010-11-25 2012-05-31 Imnate Sarl Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
BR112014009962A2 (pt) * 2011-10-27 2019-09-24 Nkt Therapeutics Inc anticorpos humanizados para inkt
CA2925878A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HK1218720A1 (zh) 2013-04-30 2017-03-10 欧缇托匹克公司 干粉制剂及使用方法
CN107531787B (zh) 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102681843B1 (ko) 2017-09-22 2024-07-05 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法
EP4480486A1 (en) * 2022-02-14 2024-12-25 Riken Nkt cell ligand-containing liposome composition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7063844B2 (en) * 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
ES2201078T3 (es) 1993-06-21 2004-03-16 Brigham And Women's Hospital Metodos de aislar antigenos presentados por cd1, vacunas que comprenden antigenos presentados por cd1, y lineas celulares para usar en dichos metodos.
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ATE286735T1 (de) * 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
JP2001515868A (ja) * 1997-09-12 2001-09-25 ブライハム アンド ウイメンズ ホスピタル Ｃｄ１制限免疫応答のための合成抗原
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
WO2000002923A1 (en) 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
AU2002213588A1 (en) 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
AU2001262697A1 (en) * 2000-06-06 2001-12-17 Kirin Beer Kabushiki Kaisha Method of amplifying natural killer t cells
DK2336187T3 (en) * 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
WO2002016825A1 (fr) * 2000-08-18 2002-02-28 Mitsubishi Denki Kabushiki Kaisha Douille et transformateur pour lampe et procede de fabrication d'un transformateur pour lampe
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
CN1487996B (zh) * 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
EP1372668B1 (en) * 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US6662434B2 (en) * 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
WO2002087556A2 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) * 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) * 2001-05-18 2002-11-21 Wegener William E. Security electronic system
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
AU2003234443A1 (en) 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
HK1079882B (en) 2002-06-14 2011-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing colitis involving il-13 and nk-t cells
US7368142B2 (en) * 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
US20060104901A1 (en) 2002-08-27 2006-05-18 Angus Moodycliffe Preventing or treating epithelial tissue damage or hair loss
WO2004028475A2 (en) 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) * 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20040235162A1 (en) * 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
WO2004094444A1 (en) * 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
ES2389080T3 (es) 2004-06-11 2012-10-23 Riken Fármaco que presenta un ligando de células reguladoras contenido en el liposoma

Also Published As

Publication number Publication date
WO2006060117A3 (en) 2007-03-01
CA2584971A1 (en) 2006-06-08
DK1812015T3 (en) 2013-01-02
CA2584971C (en) 2013-08-06
US7682614B2 (en) 2010-03-23
US20100197613A1 (en) 2010-08-05
CN101031307A (zh) 2007-09-05
US20060116332A1 (en) 2006-06-01
EP1812015B1 (en) 2012-01-04
PT1812015E (pt) 2012-02-20
US8679499B2 (en) 2014-03-25
ES2378076T3 (es) 2012-04-04
WO2006060117A2 (en) 2006-06-08
EP1812015A4 (en) 2008-02-20
JP2008518974A (ja) 2008-06-05
AU2005310247A1 (en) 2006-06-08
ATE539757T1 (de) 2012-01-15
CN101031307B (zh) 2012-09-05
EP1812015A2 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
US8679499B2 (en) Methods for relieving asthma-associated airway hyperresponsiveness
JP6764396B2 (ja) 二糖合成脂質化合物およびその使用
Kim et al. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model
Agnihotri et al. Structure–activity relationships in Toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides
US20180105547A1 (en) Methods for the treatment and prevention of inflammatory diseases
US20240076393A1 (en) Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
JP4804626B2 (ja) 免疫レギュレータ
Chaby Strategies for the control of LPS-mediated pathophysiological disorders
Xu et al. Low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways
JP2009520730A (ja) アレルギー性疾患を治療および予防するための手段および方法
US20100204295A1 (en) Treatment of allergic disease with immunomodulator compounds
AU2011250800B2 (en) Methods for inhibition of NKT cells
WO2009135001A2 (en) Methods and compositions for regulating th2 and th17 responses
WO2016144760A1 (en) Compositions and methods for treating allergic inflammation
US20100035843A1 (en) Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US20130281409A1 (en) Myelin Sheath Fatty Acids that Resolve Neuroinflammation
WO2009015279A2 (en) Agents and methods for inhibition of airway hyperresponsiveness
Van Rensburg Immunoactive, Antibacterial and Drug-Carrying properties of selective surfactants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120216

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120306

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150316

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees